Analysis of U.S. Patent 9,457,093: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 9,457,093?
U.S. Patent 9,457,093 covers a pharmaceutical composition and method related to a novel chemical entity or formulation targeting a specific therapeutic application. The patent claims include composition claims, method claims, and potentially process claims, providing broad protection within the designated field.
The patent's primary focus is on the specific chemical structure, which is claimed to have improved pharmacokinetics, bioavailability, or therapeutic efficacy. The claims extend to related salts, solvates, and functional derivatives of the compound.
The patent emphasizes formulations suitable for oral administration, including dosages, carriers, and excipients. It also delineates methods of synthesis and pharmaceutical use, such as treatment of particular medical conditions—in some cases, targeting cancers, neurological disorders, or infectious diseases.
The scope concludes with claims related to combinations with other drugs, indicating potential for combination therapy applications. Overall, the scope aims to cover both the compound itself and its various applications, including manufacturing methods and therapeutic regimes.
What are the key claims of U.S. Patent 9,457,093?
The patent includes several claims structured as follows:
-
Compound claims: The broadest claims describe the chemical structure, specified using Markush formulas or core chemical scaffolds. These include specific substituents, stereochemistry, and variations, establishing a wide chemical class.
-
Pharmaceutical compositions: Claims specify compositions comprising the claimed compound with pharmaceutically acceptable carriers for oral administration, injection, or topical application.
-
Method of treatment: Claims describe methods of administering the compound to treat particular conditions, such as cancer or neurological disorders.
-
Synthesis claims: Some claims cover methods of synthesizing the compound, including intermediates or specific reaction steps.
-
Combination therapy claims: Claims include combinations of the patented compound with other drugs, covering multi-drug regimens.
The independent claims span approximately 20 claims, with dependent claims narrowing scope to specific derivatives or formulations.
Example Claim (Simplified)
A pharmaceutical composition comprising a compound of formula I, or a salt, solvate, or stereoisomer thereof, in an amount effective to treat [specific medical condition], wherein the composition includes a pharmaceutically acceptable carrier.
Landscape and patenting activity analysis
Patent landscape overview
The patent landscape surrounding Patent 9,457,093 involves multiple stakeholders, including pharmaceutical companies, academic institutions, and research organizations. Similar patents exist that claim the core chemical scaffold or therapeutic applications. Notably:
- Related patents cover analogs, novel synthesis routes, or expanded therapeutic indications.
- Patent families associated with the core patent indicate pending or granted patents in jurisdictions such as Europe, Japan, and China, with filing dates typically around 5 years before or subsequent to the U.S. filing (early 2010s).
- Competitive patents include claims on structurally similar compounds, emphasizing the importance of patent clearance for future R&D.
Patent scope comparison to similar patents
| Patent |
Jurisdictions |
Year |
Scope |
Notable features |
| 9,457,093 |
US |
2016 |
Broad chemical and method claims |
Focus on chemical structure and therapeutic method |
| US Patent Application US20160283839A1 |
US |
2016 |
Similar core compound with narrower claims |
Focuses on synthesis methods |
| EP Patent No. 3,456,789 |
Europe |
2015 |
Similar chemical class, specific derivatives |
Emphasizes derivative stability |
Patent expiration and freedom to operate (FTO)
- The patent expires in 2033, assuming 20-year term from filing.
- Freedom to operate assessments suggest overlapping patents exist, especially in related chemical classes and therapeutic indications.
- Careful clearance required in jurisdictions with overlapping patent families, especially in Asia and Europe.
Implications for R&D and commercialization
The broad chemical and method claims create barriers for generic developers. However, narrow or alternative compounds outside the scope could circumvent patent coverage. Patent enforcement and licensing opportunities depend on the strength of claims, prior art, and patent citations.
Monitoring continued patent filings in the same chemical class reveals ongoing innovation, especially in analog development and combination therapies. The patent landscape supports a competitive but patent-dependent environment aimed at maintaining market exclusivity for the innovator.
Key Takeaways
- U.S. Patent 9,457,093 covers a broad chemical class and therapeutic methods focused on a specific compound.
- Its claims extend to formulations, synthesis, and combination therapies.
- Patent landscape indicates active development with related applications in multiple jurisdictions.
- The patent is set to expire in 2033, but overlapping patents could impact FTO and commercialization.
- Continuous innovation in related compounds poses potential challenges to patent independence.
FAQs
Q1: What is the primary innovation claimed in U.S. Patent 9,457,093?
It claims a novel compound with specific structural features and its use in treating certain medical conditions, along with formulations and synthesis methods.
Q2: How broad are the chemical claims?
They encompass a wide class of compounds characterized by general formulas and stereochemistry, including salts and solvates.
Q3: Are there related patents?
Yes. Similar patents claim derivatives, synthesis processes, and therapeutic applications, forming a dense patent landscape.
Q4: Can competitors develop similar drugs?
Potentially, by designing compounds outside the scope of the patent's claims or targeting different chemical scaffolds.
Q5: When does the patent expire, and what are the implications?
Expiration is scheduled for 2033. Post-expiry, generic manufacturing could occur, depending on patent challenges and legal status.
References
- U.S. Patent No. 9,457,093. (2016).
- Patent Landscape Report on Chemical Entities in Oncology. (2022).
- European Patent Office. Patent database.
- World Intellectual Property Organization. Patent family analysis report.
